Investors

Important Notice

CELLECT Announces today (Sep 20, 2018) It will Hold an Extraordinary General Meeting to Elect a New External Director

On September 20, 2018, Cellect Biotechnology Ltd. (the “Company”) announced that on October 25, 2018 it will hold at the offices of Doron, Tikotzky, Kantor, Gutman & Amit Gross, at B.S.R 4 Tower, 33 Floor, 7 Metsada Street, Bnei Brak, Israel an extraordinary general meeting to be held at 11:00 a.m. Israel time, or at any adjournment. The extraordinary meeting is being called to elect Jonathan Burgin as an external director for a three-year term commencing on the date of his election at the extraordinary meeting.

The board of directors recommends that you vote in favor of the proposal, which is described in the attached Proxy Statement. Shareholders and American Depositary Share (the “ADSs”) holders of record at the close of business on September 27, 2018 (the “Record Date”), are entitled to notice of and to vote at the extraordinary meeting either in person or by appointing a proxy to vote in their stead at the extraordinary meeting.

Shareholders registered in the Company’s shareholders’ register in Israel, and shareholders who hold ordinary shares through members of the Tel Aviv Stock Exchange, may also vote through the attached proxy by completing, dating, signing and mailing the proxy to the Company’s offices, so that is received by the Company no later than four hours prior to the scheduled date of the extraordinary meeting.

Shareholders registered in the Company’s shareholders register in Israel, and shareholders who hold ordinary shares through members of the Tel Aviv Stock Exchange who vote their ordinary shares by proxy, must also provide the Company with a copy of their identity card, passport or certification of incorporation, as the case may be.

Shareholders who hold shares through members of the Tel Aviv Stock Exchange and intend to vote their ordinary shares either in person or by proxy must deliver to the Company, no later than four hours prior to the scheduled date of the extraordinary meeting, an ownership certificate confirming their ownership of the Company’s ordinary shares on the Record Date, which certificate must be approved by a recognized financial institution, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting) 4760 - 2000, as amended.

ADS holders should return their proxies by the date set forth on their voting instruction card. To the extent you would like to submit a position statement with respect to any of proposals described in the Proxy Statement pursuant to the Israeli Companies law, 1999, you may do so by delivery of appropriate notice to Company’s offices (Attention: Chief Financial Officer) located at 23 Hata’as Street Kfar Saba, Israel 44425, Israel, not later than ten days before the extraordinary meeting date (i.e., October 15, 2018).

Attached and available for download are:

  1. Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders;
  2. Proxy Card for holders of ordinary shares with respect to the Company’s Extraordinary General Meeting of Shareholders;
  3. Voting Instruction Card for holders of the Company’s ADS holders with respect to the Company’s Extraordinary General Meeting of Shareholders.

Stock Quote

Corporate Presentation

October 2018
Click to Download

SEC Filings

Click Here

Corporate Governance

The Board of Directors of Cellect Biotechnology Ltd (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.